Guardant Health

@Spokavriel @PreventionMag @Spokavriel We can confirm Patrick Dempsey is not Dale. Thanks for the interest in our campaign and for watching so closely!

@PreventionMag Ran out of space for @GuardantHealth they re-posted the Prevention video. And would know the answer to who is in the ad.

Patrick Dempsey on the ‘Real Gaps’ in Cancer Care—and How He’s Working to Close Them prevention.com/health/health-…

We’re looking forward to joining the oncology nursing community this week at #ONSCongress 2026. Stop by booth 743 to connect with our team and learn how ctDNA testing and liquid biopsy insights are helping inform #PrecisionOncology. We’ll also host two sessions of our educational event, From detection to decision: the role of ctDNA in oncology care, during the meeting: Thursday, May 14 | 6:00PM CT: bit.ly/4nwBC8z Friday, May 15 | 6:00PM CT: bit.ly/42rEytu

At #MIGlobal, our chairman and co-CEO Helmy Eltoukhy discussed the next wave of health innovation and how advances in diagnostics, AI, and large-scale data are accelerating a shift toward earlier, more actionable cancer care. As Helmy shared, diagnostics already inform the majority of medical decisions, yet the healthcare system still invests far more heavily in treating disease after it progresses than detecting it earlier. The future of cancer care has to look different. Helmy shared a powerful example of what happens when technology compounds and the kind of progress that can help bend the healthcare cost curve. Watch the full session: bit.ly/48OKcte

Yesterday, we shared our first quarter 2026 financial results, with 48% year-over-year revenue growth driven by strong performance across our Oncology and Screening businesses. This included significant growth across Guardant360® Liquid and Guardant360® Tissue testing, strong receptivity to our expansion into therapy response monitoring with Guardant Reveal®, and increasing Shield™ volumes as we continue working to bring precision oncology and cancer screening solutions to more patients. Details: bit.ly/4uVYz7R

We’re excited to share that we've been recertified as a Great Place To Work® in the U.S. for the fourth year in a row — a reflection of the people, purpose, and culture that drive us forward every day as we work to conquer cancer with data. #ThankYou to everyone across Guardant® whose passion, dedication, and collaboration make this recognition possible.

#Leadership today is defined by more than outcomes. Later today, our co-CEO AmirAli Talasaz joins leaders at the @MilkenInstitute Global Conference for an invite-only discussion on how reputation, trust, and culture are shaping resilient organizations. #MIGlobal session details: bit.ly/4d3fv4L

The next wave of health innovation is already taking shape. This afternoon, our Chairman and co-CEO Helmy Eltoukhy will join leaders at the @MilkenInstitute Global Conference to discuss the technologies redefining what’s possible in healthcare—from AI-enabled discovery to multimodal data platforms and next-generation diagnostics. Turning these advances into impact will require clarity across regulation, sustainable models for access, and continued investment in innovation. Watch the #MIGlobal session live: bit.ly/4cQSpQ9

We’re proud to share the FDA’s approval of Guardant360® CDx as a companion diagnostic for VEPPANU (vepdegestrant) for patients with ER+/HER2- advanced #BreastCancer with ESR1 mutations, marking our third ESR1 companion diagnostic FDA approval. Details: bit.ly/4tJNbLS

Strong alignment across healthcare leaders is how innovation reaches patients faster. At the @USChamber 2026 Health Summit, our Co-CEO AmirAli Talasaz shared why the pace of innovation—from genomics to AI—is accelerating, and what it will take to ensure access keeps up with the science. When policy and innovation move together, the impact for patients is real.

A collaboration shaped by the expanding role of precision diagnostics in oncology drug development. Today, we announced a multi-year collaboration with @nuvalent to advance clinical development and companion diagnostic strategies using the tissue and liquid offerings of our Guardant Infinity™ platform. Details: bit.ly/4eTBQUW

#ColorectalCancer screening isn’t just a clinical conversation. It’s a community one. In our latest blog, we share how we’re partnering with the First Ladies Health Initiative to bring that critical conversation forward through trusted voices and real stories that empower people to take control of their health. Because when awareness meets trust, more people take action. Read more: bit.ly/4865Fxu

Join us for a live clinical education #Webinar exploring how emerging ctDNA evidence may reshape management of HR+/HER2- metastatic #BreastCancer. Guardant Health clinical leadership & expert oncologists will discuss insights from the SERENA-6 trial and the evolving role of ESR1 monitoring in treatment decision-making. 📅 Date: Wednesday, April 15 🕚 Time: 11:00am PT Register today: bit.ly/4cl7uZQ

We commend ASMM for leading the development of a practical, forward-looking framework to modernize screening quality measures—so patients don’t have to wait years to benefit from innovation. A more timely, evidence-based approach can help close access gaps by ensuring quality programs keep pace with advancements, including 2024 FDA-approved colorectal cancer screening tests, and expand access to modern screening options for patients. Read more: rubrumadvising.com/resource/asmm-…

As #ColorectalCancerAwarenessMonth comes to a close, our Co-CEO AmirAli Talasaz reflects on a decade-long journey to advance #ColorectalCancer screening—and the work still ahead. From breakthrough innovation to expanding access, early detection remains critical as we work to close the screening gap and reach more patients. Read his perspective below 👇guardanthealth.com/2026/03/31/ref…

Real-world evidence is shaping what comes next in #PrecisionOncology. Evidence generated from our InfinityAI platform contributed to the recent approval of ENHERTU® in Japan for previously treated patients with HER2-positive metastatic solid tumors—highlighting how real-world evidence is gaining traction with regulators and opening new pathways in rare, biomarker-defined populations. Read more: bit.ly/4talsn0

#AACR26 is on the horizon, and we’re set to share 28 abstracts showcasing advances in methylation-based tumor classification, therapy selection, and the expanded utility of multiomic tissue and #LiquidBiopsy testing as the global #CancerResearch community comes together in San Diego, April 17–22. More details: bit.ly/4sVxWyD

Shield Across America makes a Vegas pit stop at the Pennzoil 400 🏁 #CRCAwarenessIntoAction news3lv.com/news/local/pen…